Have a feature idea you'd love to see implemented?
Let us know!
CLSD Clearside Biomedical Inc
Price (delayed)
$1.31
Market cap
$97.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.5
Enterprise value
$127.27M
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside's proprietary SCS
Highlights
CLSD's gross margin is up by 32% YoY and by 2.4% from the previous quarter
The EPS has grown by 15% year-on-year and by 9% since the previous quarter
CLSD's equity is down by 30% since the previous quarter
CLSD's quick ratio is down by 25% YoY and by 16% from the previous quarter
Key stats
What are the main financial stats of CLSD
Market
Valuations
Earnings
Shares outstanding
74.75M
Market cap
$97.92M
Enterprise value
$127.27M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
13.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.92
Revenue
$7.52M
EBIT
-$33.46M
EBITDA
-$33.35M
Free cash flow
-$20.16M
Per share
Balance sheet
Liquidity
EPS
-$0.5
Free cash flow per share
-$0.27
Book value per share
-$0.38
Revenue per share
$0.1
TBVPS
$0.45
Total assets
$33.93M
Total liabilities
$62.22M
Debt
$47.59M
Equity
-$28.29M
Working capital
$23.89M
Debt to equity
-1.68
Current ratio
5.07
Quick ratio
5
Net debt/EBITDA
-0.88
Margins
Efficiency
Dividend
EBITDA margin
-443.2%
Gross margin
98.1%
Net margin
-444.7%
Operating margin
-362.4%
Return on assets
-93.9%
Return on equity
N/A
Return on invested capital
-72.6%
Return on capital employed
-119.2%
Return on sales
-444.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLSD stock price
How has the Clearside Biomedical stock price performed over time
Intraday
-11.49%
1 week
-2.24%
1 month
23.58%
1 year
50.35%
YTD
11.97%
QTD
3.15%
Financial performance
How have Clearside Biomedical's revenue and profit performed over time
Revenue
$7.52M
Gross profit
$7.38M
Operating income
-$27.27M
Net income
-$33.46M
Gross margin
98.1%
Net margin
-444.7%
The operating margin has soared by 80% YoY but it is down by 14% from the previous quarter
CLSD's net margin has surged by 80% year-on-year but it is down by 7% since the previous quarter
CLSD's gross margin is up by 32% YoY and by 2.4% from the previous quarter
The revenue has contracted by 11% from the previous quarter
Growth
What is Clearside Biomedical's growth rate over time
Valuation
What is Clearside Biomedical stock price valuation
P/E
N/A
P/B
N/A
P/S
13.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.92
The EPS has grown by 15% year-on-year and by 9% since the previous quarter
CLSD's equity is down by 30% since the previous quarter
The P/S is 53% below the 5-year quarterly average of 27.7 and 11% below the last 4 quarters average of 14.7
The revenue has contracted by 11% from the previous quarter
Efficiency
How efficient is Clearside Biomedical business performance
The return on sales has surged by 80% year-on-year but it has declined by 7% since the previous quarter
Clearside Biomedical's return on invested capital has increased by 31% YoY and by 14% QoQ
The company's return on assets fell by 25% YoY
Dividends
What is CLSD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLSD.
Financial health
How did Clearside Biomedical financials performed over time
The company's total assets is 45% lower than its total liabilities
The total liabilities is up by 41% YoY
The current ratio has contracted by 26% YoY and by 16% from the previous quarter
The debt to equity has soared by 79% YoY and by 19% from the previous quarter
CLSD's equity is down by 30% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.